Entry into a Material Definitive Agreement. On August 24, 2026, Autonomix Medical, Inc. (the “Company”) entered into a warrant inducement offer letter (the “Inducement Letter”) with the holder (the “Holder”) of certain existing Series D-1 warrants and Series D-2 warrants issued on July 15, 2026, to purchase up to 857,462 shares of Company common stock (the “Existing Warrants”). Pursuant to the Inducement Letter, the Holder agreed to exercise the Existing Warrants to purchase an aggregate of 8…

Unregistered Sales of Equity Securities. The Company issued the New Warrants pursuant to the exemption from the registration requirements of the Securities Act available under Section 4(a)(2). Neither the issuance of the New Warrants nor the New Warrant Shares will be registered under the Securities Act, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws. Th…

Material Modifications of Rights of Security Holders To the extent required by

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 14, 2026, Autonomix Medical, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the closing bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the N…

Entry into a Material Definitive Agreement. On November 18, 2025, Autonomix Medical, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Agreement”) with an institutional investor (the “Investor”), pursuant to which the Investor purchased in a private placement: (i) pre-funded warrants to purchase 4,501,666 shares of the Company’s common stock, $0.001 par value per share (“Common Stock”) (the “Pre-Funded Warrants”); and (ii) Series C Warrants to purchase up to an aggregate…

Unregistered Sales of Equity Securities. The information set forth in

In the Purchase Agreement, Lincoln Park represented to the Company, among other things, that it is an “accredited investor” (as such term is defined in Rule 501(a)(3) of Regulation D under the Securities Act of 1933. The Commitment Shares were issued and the Purchase Shares will be issued and sold by the Company to Lincoln Park in reliance upon the exemptions from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulatio…

Entry into a Material Definitive Agreement. On August 25, 2025, Autonomix Medical, Inc. (the “Company”) entered into a purchase agreement, dated as of August 25, 2025 (the “Purchase Agreement”), with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park committed to purchase up to $15.0 million in shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), subject to satisfaction of the conditions and certain limitations contained in the Pu…

Entry into a Material Definitive Agreement. On July 21, 2025, Autonomix Medical, Inc. (the “Company”) entered into a warrant exercise inducement offer letter (the “Inducement Letter”) with the holders (“Holders”) of certain existing warrants issued in November 2024 to purchase up to 1,477,596 shares of Company common stock (the “Existing Warrants”). Pursuant to the Inducement Letter, the Company agreed to reduce the exercise price of the Existing Warrants to $1.723 per share, and the Holders…

Unregistered Sales of Equity Securities. The Company will issue the Inducement Warrants pursuant to the exemption from the registration requirements of the Securities Act available under Section 4(a)(2). Neither the issuance of the Inducement Warrants nor the Inducement Warrant Shares will be registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable s…

Entry into a Material Definitive Agreement. On February 28, 2025, Autonomix Medical, Inc. (the “Company”) entered into an At Market Issuances Sales Agreement (the “Agreement”) with Ladenburg Thalmann & Co. Inc. (the “Agent”). Pursuant to the terms of the Agreement, the Company may sell from time to time through the Agent, as sales agent or principal, shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) with an initial aggregate sales price of up to $2.1 million (t…

Results of Operations and Financial Condition On February 13, 2025, Autonomix Medical, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter of fiscal year 2025 ended December 31, 2024 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference. Some of the statements in the conference presentation are forward-looking statements within…

Entry into a Material Definitive Agreement. On November 22, 2024, Autonomix Medical, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Ladenburg Thalmann & Co. Inc., as representative of the several underwriters, if any, named on Schedule I of the Underwriting Agreement (the “Underwriters”), in connection with a firm commitment underwritten public offering (the “Offering”) of: (i) 458,691 common units (the “Common Units”), each Common Unit consist…

Results of Operations and Financial Condition On November 11, 2024, Autonomix Medical, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended September 30, 2024 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

Material Modifications of Rights of Security Holders. To the extent required by

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 16, 2024, Autonomix Medical, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the closing bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the…

Results of Operations and Financial Condition On August 13, 2024, Autonomix Medical, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter of fiscal year 2025 ended June 30, 2024 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

Entry into a Material Definitive Agreement. On July 10, 2024, Autonomix Medical, Inc. (the “Company”) entered into a license agreement (the “Agreement”) with RF Innovations, Inc. (“RFI”), a privately held medical technology company, to license products utilizing RFI’s intellectual property related to its Apex 6 Radiofrequency Generator (the “Licensed Products”). The Apex 6 Generator is an FDA-cleared ablation technology designed to lesion neural tissue for pain management in the peripheral ne…

Unregistered Sales of Equity Securities. The common stock to be issued to RFI pursuant to the Agreement will be issued pursuant Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and will not been registered under the Securities Act or applicable state securities laws.

The filing details changes in compensation and option grants for certain officers.

CEO and President — Brad Hauser: The company hired a new CEO and President with significant compensation and equity incentives.

Unregistered Sales of Equity Securities The information contained below in

Results of Operations and Financial Condition On May 31, 2024, Autonomix Medical, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended March 31, 2024 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference. Some of the statements in the conference presentation are forward-looking statements within…